May 31, 2016
(Med Page Today) – When doctors try to figure out whether a patient might become addicted to opioid painkillers, they rely on clinical risk factors like family history, medical history, and other social and environmental clues. Now, two companies — Proove Biosciences and Canterbury Healthcare’s Innovative Medical Testing (IMT) — want to add genetic information to that picture in order to improve risk prediction. But academic geneticists say they may be getting ahead of the science.
The views, opinions and positions expressed by these authors and blogs are theirs and do not necessarily represent that of the Bioethics Research Library and Kennedy Institute of Ethics or Georgetown University.